Experimental study of new pyrazolo[3,4-D]pyrimidine-4-one derivatives for anticonvulsant activity spectrum
DOI:
https://doi.org/10.15587/2519-4852.2016.70528Keywords:
pyrazolo[3, 4-d]pyrimidin-4-one derivatives, anticonvulsant activityAbstract
Aim. To determine an effective dose range of three compounds of pyrazolo[3,4-d]pyrimidin-4-one derivatives in a basic pentylenetetrazole-induced seizure model and spectrum of anticonvulsant activity in experimental models of seizure with different pathogenetic mechanisms.
Materials and methods. The experiments were performed on 240 mature albino male mice weighing 19–29 g. The dose dependence was investigated on a basic screening model of pentylenetetrazole-induced seizures on mice. Mice were exposed to electrical stimuli lasting for 0.2 s (50 Hz, 50mA) using corneal electrodes in another conventional maximal electroshock seizure model. A neurotransmitter profile of the leading compound effect was determined in picrotoxin-, thiosemicarbazide, strychnine- and caffeine-induced seizure models. Compounds and reference-drug were administered intragastrically 30 min before a subcutaneous (for picrotoxin and strychnine) or an intraperitoneal (for caffeine and thiosemicarbazide) convulsant administration.
Results. Compound 78553 (200 mg/kg) and compound 78342 (100 mg/kg) have demonstrated the most marked anticonvulsant properties in the pentylenetetrazole-induced seizure model which effects are comparable to those of valproate sodium (300 mg/kg). Only compound 78553 (1-(4-metoxyphenyl)-5-{2-[4-(4-metoxy-phenyl)piperazine-1-yl]-2-oxoethyl}-1,5-dihydro-4H-pyrazole[3,4-d]pyrydine-4-one) had a moderate anticonvulsant effect in maximal electroshock seizure test. In seizure models with different pathogenetic mechanisms the compound 78553 has demonstrated an obvious effect on caffeine-induced seizures, moderate effect on picrotoxin-induced seizures (at relatively low dose of anticonvulsant), and insignificant effect on strychnine-induced seizures.
Conclusions. The spectrum of anticonvulsant activity results of the leading compound 78553 in the seizure models with different pathogenesis has shown its potential mechanisms to include a stimulated effect on GABAergic processes (antagonism to pentilenetetrazole), as well as antagonism to blocking GABA-activated chloride channels (moderate antagonism to picrotoxin), on the adenosinergic link (marked antagonism to caffeine) and on the neural membrane permeability to sodium (moderate reduction of a maximum electroconvulsive seizure). Glycinergic action (moderate antagonism to strychnine convulsive effect) may play a minor role. The study compound has produced no effect on thiosemicarbazide-induced seizuresReferences
- The World Health Organization 2016. Fact Sheets. Available at: http://www.who.int/mediacentre/factsheets/fs999/ru/
- Gorachuk, V. V. (2011). Medical, social and economic aspects of epilepsy. Ukr. Med. Chasopys, 5, 42–44.
- Wang, S.-B., Piao, G.-C., Zhang, H.-J., & Quan, Z.-S. (2015). Synthesis of 5-Alkoxythieno[2,3-e][1,2,4]triazolo[4,3-c]pyrimidine Derivatives and Evaluation of Their Anticonvulsant Activities. Molecules, 20 (4), 6827–6843. doi: 10.3390/molecules20046827
- Wang, S.-B., Deng, X.-Q., Zheng, Y., Yuan, Y.-P., Quan, Z.-S., Guan, L.-P. (2012). Synthesis and evaluation of anticonvulsant and antidepressant activities of 5-alkoxytetrazolo[1,5-c]thieno[2,3-e]pyrimidine derivatives. European Journal of Medicinal Chemistry, 56, 139–144. doi: 10.1016/j.ejmech.2012.08.027
- Severina, A. I., Georgiyants, V. А., Shtrygol, S. Yu., Kavraiskyi, D. P. (2015). Synthesis and alkylation of 1-aryl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones as possible anticonvulsant agents. Der Pharma Chemica J., 7 (11), 43–48.
- Severina, G. I., Kavrajs'kyj, D. P., Shtrygol', S. Ju., Georgijanc, V. A. (2015). Patent UA 103378 utility model IPC (2015.01) A61K31 / 505 (2006.01) 21/00 A61R 5-R-1-aryl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-ones, which have anticonvulsant activity. № u2015 06663; appl. 06.07. 2015; publ. 10.12. 2015; Byul. № 23, 6.
- Golovenko, M. Ya., Gromov, L. O. (2003). Pre-clinical specific activity study of potential antiepileptic drugs. Kyiv: Avicenna, 26.
- Mironov, A. N., Bunyatyan, N. D., Vasil'eva, A. N. et. al (Eds.) (2012). Guidelines for conducting pre-clinical trials of medicine. Part I. Мoscow: Grif and C, 944.
- Marangos, P. J., Martino, A. M., Paul, S. M., Skolnick, P. (1981). The benzodiazepines and inosine antagonize caffeine-induced seizures. Psychopharmacology, 72 (3), 269–273. doi: 10.1007/bf00431829
- Shtrygol', S. Yu. (2007). Pharmacological effects modulation at different salt regimens. Kharkiv: Avista – VLT, 360.
- Sylkina, I. V., Gan'shina, T. S., Seredenin, S. B., Virzoyan, R. S. (2005). GABAergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon. Experimental and Clinical Pharmacology, 68 (1), 20–24.
- Newland, C. F., Cull-Candy, S. G. (1992). On the mechanism of action of picrotoxin on GABA receptor channels in dissociated sympathetic neurones of the rat. The Journal of Physiology, 447 (1), 191–213. doi: 10.1113/jphysiol.1992.sp018998
- De Deyn, P. P., D’Hooge, R., Marescau, B., Pei, Y.-Q. (1992). Chemical models of epilepsy with some reference to their applicability in the development of anticonvulsants. Epilepsy Research, 12 (2), 87–110. doi: 10.1016/0920-1211(92)90030-w
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Дмитро Павлович Каврайський, Сергій Юрійович Штриголь, Вікторія Акопівна Георгіянц, Ганна Іванівна Северіна
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.